Search Within

Bone Marrow Transplant

Formats
  1. Meeting Abstract (1398)
  2. Journal Article (1092)
  3. Review (58)
  4. Research Letter (36)
  5. Book Section (31)
  6. Guidelines (24)
  7. Editorial (20)
  8. Conference Paper (14)
  9. Correspondence (13)
  10. Book Whole (1)
  11. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (2688)
  2. Department of Medicine (2688)
  3. Hematologic Malignancies, Division of (2572)
  4. Survivorship Research (1226)
  5. GSK Faculty (882)
  6. CTCR Scholars (739)

More Groups

People
  1. Sergio Giralt (981)
  2. Miguel-Angel Perales (830)
  3. Ann Jakubowski (449)
  4. Sean Devlin (424)
  5. Esperanza Papadopoulos (405)
  6. Heather Landau (370)

More People

Years
  1. 2024 (22)
  2. 2023 (243)
  3. 2022 (201)
  4. 2021 (176)
  5. 2020 (208)
  6. 2019 (208)

More Years

Publications
  1. Blood (792)
  2. Biology of Blood and Marrow Transplantation (516)
  3. Bone Marrow Transplantation (159)
  4. Journal of Clinical Oncology (108)
  5. Transplantation and Cellular Therapy (96)
  6. Blood Advances (71)

More Publications

Publishers
  1. American Society of Hematology (869)
  2. Elsevier Inc. (727)
  3. Nature Publishing Group (230)
  4. American Society of Clinical Oncology (111)
  5. Wiley Blackwell (63)
  6. Taylor & Francis Group (61)

More Publishers

Results (2688)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk acute myeloid leukemia (AML) and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) maintenance post-hematopoietic cell transplant (HCT)
    Meeting Abstract

    DiPersio, J.; Cooper, B. W.; Suh, H. C.; Koura, D.; Bernard, L.; Shah, N. N.; Walter, R. B.; Perales, M. A.; Mapara, M.; Tamari, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) who had received 2-4 prior regimens: Updated results from the phase 3 KarMMa-3 trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A personalized whole genome-informed assay targeting single mutant in circulating tumor DNA can identify MRD and predict relapse in DLBCL
    Meeting Abstract

    Merryman, R. W.; Rhoades, J.; Xiong, K.; Antel, K.; An, H. H.; Redd, R. A.; McDonough, M. M.; Guerrero, L.; Crnjac, A.; Sridhar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G. S.; Kim, H. T.; O'Connor, S.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; El-Jawahri, A.; McAfee, S.; Hem, J.; Lozano, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with triple-class-exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who received at least 3 lines of prior antimyeloma regimens in the KarMMa-3 phase 3 randomized controlled trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed/refractory classic Hodgkin lymphoma: Results from a multicenter cohort
    Meeting Abstract

    Desai, S. H.; Merryman, R. W.; Shah, H.; Pederson, L. D.; Geyer, S. M.; Ganesan, N.; Chang, T.; Othman, T.; Falade, A. S.; Shah, G. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell LyLisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma: Real world analysis from the Cell Therapy Consortiummphoma: Real World Analysis from the Cell Therapy Consortium
    Meeting Abstract

    Riedell, P. A.; Grady, C.; Nastoupil, L. J.; Luna, A.; Ahmed, N.; Maziarz, R. T.; Hu, M.; Brower, J.; Hwang, W. T.; Schuster, S. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes of brexucabtagene autoleucel ( brexu-cel) for relapsed or refractory (R/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): Evidence from the CIBMTR registry
    Meeting Abstract

    Bezerra, E.; Itani, T.; Wudhikarn, K.; Perales, M. A.; Yang, Y.; Gergis, U.; Aribi, A.; Hill, L. C.; Jain, N.; Leonard, J. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • SHLA-DRB1 HED is associated with improved survival and decreased relapse in patients with hematologic malignancies following allogeneic hematopoietic stem cell transplant
    Meeting Abstract

    Camacho-Bydume, C.; Wang, T.; Chowell, D.; Krishna, C.; Shaffer, B. C.; Marsh, S.; Paczesny, S.; Gadalla, S. M.; He, M.; Bolon, Y. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • IL-33 induces Paneth cell production of EGF and soluble ST2, regulating epithelial regeneration after intestinal injury
    Meeting Abstract

    Calafiore, M.; Fu, Y. Y.; Vinci, P.; Arnhold, V.; Chang, W.; Jansen, S.; Egorova, A.; Takashima, S.; Kuttiyara, J.; Ito, T.; more...
    Blood (2023)

    Fulltext@MSK | Save